Nixon Gwilt Law Welcomes Seasoned Food and Drug Attorney Mark Mansour to Firm

Mansour fills the growing need for expertise in the Software as a Medical Device (SaMD) market

Washington, D.C, District of Columbia Dec 1, 2021 (Issuewire.com)  - Mark Mansour, Esq., joined Nixon Gwilt Law (NGL) as Senior Healthcare Innovation Counsel on December 1, 2021. Prior to joining NGL, Mansour served as in-house counsel to two major multinationals, gaining a sterling reputation for his innovative, business-focused approach to solving problems as well as his strong client relations skills. 

Mansour is highly experienced in securing FDA approvals for drugs and devices, working through drug and device safety issues, managing recalls, solving market access challenges, and addressing food and nutrition issues. He also advises biotechnology, nanotechnology, dietary supplement, agribusiness, and cannabis product clients on state and federal regulatory compliance. With extensive experience working with clients to address social media regulation and corporate website FTC compliance, Mark also helps clients resolve advertising issues involving the National Advertising Division (NAD) and the Federal Trade Commission. 

Mark received his BS from Georgetown University, an MA from Harvard University, and his law degree from Georgetown University. Mark is admitted to practice in the District of Columbia and Michigan, and he will serve clients from his office in the DC area.

NGL Partner Rebecca Gwilt says, “Mark's decade of experience in FDA law and his deeply pragmatic approach to client service is a perfect fit for Nixon Gwilt. We're eager to incorporate his creativity and deep industry knowledge to help drive growth for our innovative digital health, medical device, and decentralized clinical trial (DCT) clients.”

Managing Partner Carrie Nixon adds, “Mark really gets the direction we are taking the firm— and that is straight to #1 as the top healthcare innovation firm in the nation."

Mansour says that he not only chose Nixon Gwilt Law because of the quality of the firm and its lawyers but also because of the quality of their customer service, which he values highly.

NGL seeks attorneys who are forward-thinking, tech-savvy, and entrepreneurial, just like their clients. With his broad experience in Food and Drug Law and multinational experience, Mansour is uniquely positioned to create a bridge between the FDA and innovations in Life Sciences, Distributed Clinical Trials, and Medical Devices.

paidpost

Media Contact

Nixon Gwilt Law betsy.talbot@nixongwiltlaw.com 1 703-591-3166 https://nixongwiltlaw.com
Categories : Biotech , Health , Legal , Medical , Science
Tags : SaMD , FDA , Distributed Clinical Trials , Food and Drug Law , Medical Devices , healthcare innovation , FTC , biotechnology , nanotechnology , National Advertising Division

Nixon Gwilt Law

Founded in 2016, Nixon Gwilt Law works with innovative Providers, Digital Health Businesses, Life Sciences Businesses, Investors, Startups, and Growth Stage Businesses to improve patient access, options, and health outcomes. Their industry leadership in pricing by client outcomes instead of billable hours, as well as their focus on building integral “thought partner” relationships with their world-changing clients, make Nixon Gwilt Law a top choice for novel and disruptive healthcare and life science companies.
betsy.talbot@nixongwiltlaw.com
Virginia, Vienna
1 703-591-3166
https://nixongwiltlaw.com
Report Spam